USA |NASDAQ |USD
| Report Date | Period Ending | EPS Forecast | Last Quarter's EPS | Last Year's EPS |
|---|---|---|---|---|
| Nov 10, 2021 | Sep 2021 | $0.29 | $0.24 | $-0.14 |
| Report Date | Period Ending | Revenue Forecast | Last Quarter’s Revenue | Last Year’s Revenue |
|---|---|---|---|---|
| Nov 10, 2021 | Sep 2021 | $80.92M | $73.82M | $45.61M |
Harmony Biosciences's next earnings date is Wednesday, Nov 10, 2021 for the fiscal quarter ending Sep 2021.
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2021 | 4 | $0.44 | $0.30 | $0.58 |
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2021 | 3 | $1.09 | $0.89 | $1.26 |
| Dec 2022 | 4 | $2.84 | $1.95 | $3.43 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Dec 2021 | 1 / 0 | $0.40 | $0.43 | $0.42 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Dec 2021 | 0 / 1 | $1.01 | $0.96 | $0.91 |
| Dec 2022 | 0 / 1 | $2.64 | $2.73 | $3.09 |
| Period End | # of Analysts | Revenue Forecast | Low Revenue Forecast | High Revenue Forecast |
|---|---|---|---|---|
| Dec 2021 | 4 | $92.27M | $87.20M | $97.80M |
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2021 | 4 | $306.69M | $298.10M | $315.60M |
| Dec 2022 | 4 | $502.68M | $440.90M | $586.20M |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Nov 10, 2021 | Sep 2021 | $0.29 | - | - |
| Aug 10, 2021 | Jun 2021 | $0.17 | $0.24 | 41.18% |
| May 11, 2021 | Mar 2021 | $-0.03 | $0.13 | 586.89% |
| Mar 25, 2021 | Dec 2020 | $0.11 | $0.25 | 138.10% |
| Nov 12, 2020 | Sep 2020 | $-0.15 | $-0.14 | 6.67% |
| Aug 19, 2020 | Jun 2020 | - | $-0.16 | - |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Mar 25, 2021 | Dec 2020 | $-0.58 | $-0.05 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Nov 10, 2021 | Sep 2021 | $80.92M | - | - |
| Aug 10, 2021 | Jun 2021 | $68.90M | $73.82M | 1.07% |
| May 11, 2021 | Mar 2021 | $57.07M | $59.67M | 1.05% |
| Mar 25, 2021 | Dec 2020 | $51.85M | $56.29M | 1.09% |
| Nov 12, 2020 | Sep 2020 | $40.07M | $45.61M | 1.14% |
| Aug 19, 2020 | Jun 2020 | - | $38.01M | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Mar 25, 2021 | Dec 2020 | $155.30M | $159.74M | 2.86% |
HRMY's next earnings date is Wednesday, Nov 10, 2021 for the fiscal quarter ending Sep 30, 2021.
According to 4 analysts, the average EPS estimation for Harmony Biosciences's next quarterly earnings is $0.29, with a low EPS estimation of $0.22, and a high estimation of $0.34.
Over the last 1 month, EPS estimates have seen 0 upward revisions and 1 downward. The EPS 1 month trend is $0.29, the last 2 month trend is $0.30, and the 3 month trend is $0.30.
Based on 3 analysts, the average revenue estimation is $80.92M, with a low revenue estimation of $77.40M, and a high estimation of $84.30M.
Harmony Biosciences's previous earnings date was Aug 10, 2021 for its fiscal quarter ended Jun 30, 2021.
HRMY's earnings per share (EPS) was $0.24, beating the consensus analysts forecast of $0.17 by 41.18%.
The EPS was higher than the previous fiscal quarter (Mar 2021) by 84.62%, and higher than the same period a year before (Jun 2020) by -245.90%.
Revenues were $73.82M, better than the forecast of $68.90M by 7.14%, up by 23.71% from the previous quarter , and up by 94.24% from the same period last year.
The company reported a net income of $14.12M.Free cash flow for the quarter was $17.87M , compared to $-87.47M last quarter and $4.83M a year before.
HRMY ended the quarter with $195.61M in total debt, an increase of 0.36% compared to the previous quarter.
Harmony Biosciences's previous annual earnings date was Mar 25, 2021 for its fiscal year ended Dec 31, 2020.
HRMY's earnings per share (EPS) was $-0.05.
Revenues were $159.74M, better than the forecast of $155.30M by 2.86%, and up by 2564.59% from previous year's revenue.
The company reported a net income of $-36.94M.
Harmony Biosciences reported a free cash flow of $-4.99M for its fiscal year, compared to $-202.59M a year ago.
The company ended the fiscal year with $194.25M in total debt, an increase of 98.32% compared to the previous year.
Get a weekly snapshot of one new investment idea from stock exchanges worldwide.
